A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Valentine Moya MacaulaySimon R LordSyed Anwer HussainJosé Pablo MarotoRobert Hugh JonesMiguel Ángel ClimentNatalie CookChia-Chi LinShian-Shiang WangDiletta BianchiniMark BaileyLaura SchliekerThomas BogenriederJohann de BonoPublished in: British journal of cancer (2023)
EudraCT number 2013-004011-41.